Phase II multicentric explorative study of Intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with standard IM therapy.
Abstract
Publication Date:
2009
CRIS type:
4.2 Abstract in Atti di convegno
List of contributors:
Russo, Domenico; Rosti, G; Martinelli, G; Malagola, Michele; Mirto, S; Turri, D; Vitolo, U; Pregno, P; Gobbi, M; Pierri, I; Di Raimondo, F; Stagno, F; FoĆ , R; Alimena, G; Breccia, M; Saglio, G; Rege Cambrin, G; De Fabritiis, P; Abruzzese, E; Fanin, R; Tiribelli, M; Galieni, P; Bigazzi, C; Liso, V; Specchia, G; Rambaldi, A; Intermesoli, T; Lauria, F; Bocchia, M; Quarta, G; Girasoli, M; Angelucci, E; Usala, E; Bosi, A; Santini, V; Colombi, C; Fogli, M; Amabile, M; De Vivo, A; B. a. c. c. a. r. a. n. i., M.
Book title:
14th Congress of the European Society of Haematology
Published in: